• support@madhedgefundtrader.com
  • Biotech Model Portfolio
  • Daily Hot Tips
  • Hot Tips Archive
  • Member Login
  • Logout
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • My Account
    • Global Trading Dispatch
    • Mad Hedge Technology Letter
    • Biotech Newsletter
    • Newsletter
    • Mad Options Trader
    • Mad Hedge AI
    • Jacquie’s Post
    • Free Newsletter / Hot Tips
    • My Profile
      • Update Password
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
april@madhedgefundtrader.com

Trade Alert – (TSLA) February 12, 2025 – TAKE PROFITS – SELL

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-12 13:58:372025-02-12 13:58:37Trade Alert – (TSLA) February 12, 2025 – TAKE PROFITS – SELL
april@madhedgefundtrader.com

February 12, 2025

Jacque's Post

 

(CBA DELIVERED A GREAT FIRST HALF PROFIT, BUT THE CEO WARNS OF STORMS ON THE HORIZON)

February 12, 2025

 

Hello everyone

 

The numbers are in for Commonwealth Bank of Australia (CBA), and they are excellent.

The bank announced better than expected first-half profits, as the bank continues to cash in on Australia’s robust housing market.

CBA’s cash net profit after tax was $5.13bn for the six months ended December 31, compared with $5.02bn a year earlier, beating market expectations of $5.06bn.

The bank has consistently illustrated disciplined operational and strategic execution, which has underpinned their performance.  Good customer relationships have seen the bank diligently respond to the needs and risks of the bank’s customer base, which has facilitated the delivery of an above-average digital experience for the customer.

Every day, the bank lends to more than 200 businesses, helps almost 400 households buy a home, and processes more than 20 million payments.

The bank controls a quarter of the country’s mortgage market.  Despite the cost-of-living concerns, the bank indicates customers are ahead on repayments.

CBA notes that any interest rate cut “should provide some relief to many households and improve business confidence.”

Home loans grew by 3 percent and business loans by 8 percent, driving operating income up 3.3 percent to $14.1bn for the six months to December 31.

CBA announced an interim dividend of $2.25 a share for its shareholders, which is five per cent higher than the interim payout last year and represents 73 per cent of cash profit.

Great profits, but the bank is cautious about the future economic landscape.

Matt Comyn, CBA’s CEO, warns that economic conditions “remain fragile”.  He notes that “private sector growth is weak, immigration is starting to slow and geopolitical uncertainties remain.”

After a conversation between Australia’s prime minister, Anthony Albanese, and Donald Trump a couple of days ago, it became clear that the two leaders agreed “on wording” in relation to US tariffs on steel and aluminium.  In other words, Donald Trump had agreed to “consider” an exemption for Australia from US tariffs on steel and aluminium.  But, in the world we live in today, words don’t seem to mean a lot, so let’s see if Mr Trump does indeed truly “consider” an exemption for Australia.

PORTFOLIO UPDATE

SELL THESE STOCKS

1/ Turning Point Brands (TPB)

Purchase Price: $56.45

Sale Price:  $67.70

Purchase Date:  01/23/25

Profit/Loss = $ 11.25 or 19.92%

2/ Powell Industries (POWL)

Purchase Price:  $290.80

Sale Price:  $210.25

Purchase Date: 01/27/25

Profit/Loss = -$80.55 or -27.69%

3/ Palantir (PLTR) (last week, I did mention that it would be wise to take some profits)

Purchase Price:  $23.00

Sale Price:  $112.62

Purchase Date:  03/20/24

Profit/loss = $89.62 or 389.65%

4/ Tesla (TSLA)

Purchase Price: $260.00

Sale Price:  $328.50

Purchase Date:  09/27/24

Profit/Loss = $68.50 or 26.34%

5/ Core Scientific (CORS)

Purchase Price:  $9.71

Sale Price:  $12.26

Purchase Date: 08/07/24

Profit/Loss= $2.55 or 26.26%

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

QI CORNER

 

 

Cheers

Jacquie

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-12 12:00:442025-02-12 13:14:35February 12, 2025
april@madhedgefundtrader.com

Trade Alert – (META) February 12, 2025 – BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-12 10:21:582025-02-12 10:21:58Trade Alert – (META) February 12, 2025 – BUY
april@madhedgefundtrader.com

February 12, 2025

Diary, Newsletter, Summary

Global Market Comments
February 12, 2025
Fiat Lux

 

Featured Trade:

(THE ABC’s OF THE VIX),
(VIX), (VXX), (SVXY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-12 09:04:302025-02-12 09:25:02February 12, 2025
Mad Hedge Fund Trader

February 12, 2025 – Quote of the Day

Diary, Newsletter, Quote of the Day

“It’s easier to get out of Cuba than to get out of Facebook,” said a market analyst.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/07/border.png 231 308 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2025-02-12 09:00:332025-02-12 09:25:52February 12, 2025 – Quote of the Day
april@madhedgefundtrader.com

February 11, 2025

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
February 11, 2025
Fiat Lux

 

Featured Trade:

(SPLICING THROUGH SKEPTICISM)

(CSRP), (VRTX), (AMZN), (TSLA)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-11 12:02:052025-02-11 12:25:37February 11, 2025
april@madhedgefundtrader.com

Splicing Through Skepticism

Biotech Letter

When I pioneered fracking technology in Texas years ago, skeptics said we were crazy. Today’s skeptics are saying the same thing about CRISPR Therapeutics (CRSP), and they’re just as wrong.

Here’s a company sitting on a $1.9 billion cash fortress, burning through a mere $100 million per quarter – giving them enough runway to circle the Earth 19 times – and yet the stock has drifted down to $40, shedding 15% since my last analysis when it was perched at $48.

Talk about the market missing the forest for the trees.

Remember when everyone thought Amazon (AMZN) was just a bookstore? Well, CRISPR Therapeutics isn’t just another biotech company – it’s the Tesla (TSLA) of gene editing, with Vertex Pharmaceuticals (VRTX) riding shotgun.

And just like Tesla wasn’t just about making electric cars, CRISPR isn’t just about Casgevy, their FDA-approved treatment for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).

Speaking of Casgevy, let’s tackle the elephant in the room. Yes, patient enrollment has been slower than a government committee deciding on lunch options. They’ve collected cells from over 50 patients by year-end, up from 20 in mid-October.

Not exactly setting speed records, but here’s what the market is missing: the Centers for Medicare and Medicaid Services just inked a deal with Vertex/CRISPR that could be a game-changer.

Why? Because 50-60% of SCD patients are on Medicaid.

But wait, there’s more happening behind the scenes. The company has been quietly building an empire across 5 clinical programs and 10 preclinical programs.

Let’s break down what’s cooking in their kitchen.

The Casgevy rollout has expanded from 35 treatment centers in October to over 50 by year-end.

Eight jurisdictions have given them the green light, including Saudi Arabia – a market where SCD is about as common as sand.

The UK just signed on for reimbursement, first for TDT in August 2024, and now for SCD.

Their CAR-T program isn’t just targeting blood cancers anymore. They’ve expanded into autoimmune diseases like Systemic sclerosis (SSc) and Idiopathic inflammatory myopathy (IIM).

We’re talking about potential treatments for 2.5 million SSc patients globally (125,000 in the US) and 1 million IIM patients (50,000 in the US).

That’s not just a market – it’s an ocean.

They’re even taking shots at liver cancer and cardiovascular diseases. Their latest trial for Heterozygous familial hypercholesterolemia could be a lifeline for patients with this genetic cholesterol disorder.

And speaking of cash runways, their $1.9 billion war chest means they can keep this scientific symphony playing for 19 quarters without passing around the collection plate.

In biotech terms, that’s like having enough food to last through three winters.

Institutions are noticing, too. Cathie Wood just backed up the truck, dropping $10 million more into CRISPR, making it her 9th largest holding at $350 million. Her ARK funds now own over 9% of the company.

When smart money moves like this, I pay attention.

Here’s the kicker: While most analysts raise their ratings as speculative stocks climb (a strategy that makes as much sense as buying umbrella futures during a drought), I’m doing the opposite.

After all, the fundamentals are stronger than ever, but the price is lower.

Looking ahead to 2025, we’ve got more potential catalysts than a chemistry textbook. Phase 1/2 trial data for CTX 112 is coming in Q2/Q3, CTX 131 in Q3/Q4, and updates on their Type 1 Diabetes program in the second half of the year.

Remember, this is the same company that has Vertex Pharmaceuticals – the biotech equivalent of having Warren Buffett as your investment advisor – as a partner.

They’re not just getting financial support; they’re getting a masterclass in how to commercialize breakthrough treatments.

The verdict? Load up on shares while the market gives us this gift wrapped in fear and uncertainty.

Twenty years ago, they called us crazy for thinking we could extract oil from solid rock. Today, they’re just as skeptical about editing genes.

History has a funny way of repeating itself.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-11 12:00:562025-02-11 12:25:24Splicing Through Skepticism
april@madhedgefundtrader.com

Trade Alert – (TSLA) February 11, 2025 – STOP LOSS – SELL

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-11 11:11:142025-02-11 11:11:14Trade Alert – (TSLA) February 11, 2025 – STOP LOSS – SELL
april@madhedgefundtrader.com

February 11, 2025

Diary, Newsletter, Summary

Global Market Comments
February 11, 2025
Fiat Lux

SPECIAL VOLATILITY ISSUE

 

Featured Trade:
(TESTIMONIAL)
(MAKING VOLATILITY YOUR FRIEND),
(VIX), (VXX), (XIV)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2025-02-11 09:06:582025-02-11 10:58:48February 11, 2025
Douglas Davenport

MY MOVE 37

Mad Hedge AI

(PLTR), (AMZN), (MSFT), (GOOG)

Last weekend, I watched my daughter absolutely demolish me in a game of Go on her smartphone. 

As I nursed my wounded pride with a cup of coffee, I couldn’t help but smile – not because I lost, but because I remembered something remarkable that happened in 2016 that changed everything we thought we knew about artificial intelligence.

You see, back then, Google’s (GOOG) AlphaGo made what became known as “move 37” against Go champion Lee Sedol. It was a move so bizarre, so seemingly nonsensical, that human experts thought it was a glitch. 

Turns out, it was pure genius. That single move didn’t just win a game – it showed us that AI could think in ways humans never imagined.

Fast forward to today, and I’m seeing something equally revolutionary happening in the AI space. 

Just like AlphaGo’s famous move, we’re witnessing what I call the “chain-of-thought revolution,” and it’s about to reshape everything we know about AI investing.

Speaking of investing, Palantir (PLTR) has once again caught my attention lately, and not just because it’s up 300% in 2024. There’s something much bigger brewing here, and it reminds me of that pivotal AlphaGo moment.

Let me break down why this matters.

Remember how the later version of AlphaGo, called AlphaGo Zero, absolutely crushed its predecessor? Here’s the kicker – it did it by completely ignoring human knowledge. 

That means pure machine learning, no human training wheels needed. This isn’t just some tech trivia – it’s a blueprint for what’s happening right now in the AI industry.

Through recent breakthroughs in what’s called “chain-of-thought” processing and reinforcement learning (RL), we’re seeing AI models that can actually improve themselves. 

Think of it like a digital version of compound interest, but for intelligence. OpenAI’s “o” series and DeepSeek-R1 are already showing us glimpses of this future.

Why is this important to us? Because we’re approaching what AI researchers call a “hard takeoff” – a moment when AI capabilities could improve exponentially. 

And just like buying Amazon (AMZN) in the early days of e-commerce, positioning yourself correctly now could be life-changing.

This brings us back to Palantir, which reported Q4 revenue of $828 million, up 36% year-over-year. 

Their U.S. commercial revenue jumped 54%, and government revenue grew 45%. 

But here’s what really got my attention – they achieved this with a 45% adjusted operating margin. Now, that’s the kind of margin most software companies only dream about.

The company is projecting $3.75 billion in revenue for 2025, representing 31% annual growth. 

Sure, at $236 billion market cap and a P/E of 525, it looks expensive. But so did Microsoft (MSFT) when it first started dominating the PC market.

Here’s why I think Palantir is uniquely positioned.

First, they’ve built what I call the “infrastructure for intelligence” – systems that can deploy these new self-improving AI models securely and at scale. It’s like owning the railroad tracks during the steam engine revolution.

Second, their government contracts provide stable cash flow while their commercial business offers explosive growth potential. It’s a rare combination that reminds me of early AWS.

Third, and most importantly, they’re perfectly positioned to benefit from the chain-of-thought revolution. While others are still figuring out how to make AI work in the real world, Palantir already has the plumbing in place.

Now, let’s talk risks because I’ve been around long enough to know nothing is a sure bet. 

Competition is fierce – Microsoft, Google, and an army of well-funded startups are all fighting for a piece of the pie. The valuation is steep, and any slowdown in growth could hit the stock hard.

But here’s what keeps me bullish: Unlike companies building the AI models themselves (which become commoditized quickly), Palantir operates on the application layer. 

They’re not selling picks and shovels during the gold rush – they’re building the entire mining infrastructure.

Think about it this way: When I was learning to code in the early days of the internet, we were writing basic HTML. 

Today, my kid who beat me at Go is creating AI agents that can write their own code. That’s the kind of exponential progress we’re seeing, and Palantir is right at the center of it.

At its current valuation, Palantir might look scary. But remember what happened when we doubted Tesla’s (TSLA) valuation? Sometimes, the market prices in the future before most investors can see it.

Just like AlphaGo’s “move 37” seemed crazy until it proved brilliant, investing in Palantir at these levels might seem nuts to some. 

But when you understand the technological revolution happening under the surface – this chain-of-thought AI breakthrough combined with reinforcement learning – the potential becomes clear.

Just like in Go, sometimes the winning move in investing isn’t the obvious one. 

And right now, while others are still learning the rules of the AI game, I’m putting my money where my mouth is and making my move with Palantir on dips.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2025-02-10 17:04:592025-02-10 17:04:59MY MOVE 37
Page 10 of 14«‹89101112›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top